A61K 38 - Medicinal preparations containing peptides

Patents for A61K 38 - Medicinal preparations containing peptides (316,240)
11/2004
11/04/2004	WO2004094589A2 Secreted proteins
11/04/2004	WO2004094472A2 Collagen fibrils carrying bioactive heterologous domains and their use in e.g. wound healing
11/04/2004	WO2004094471A2 Mediators of reverse cholesterol transport for the treatment of hypercholesterolemia
11/04/2004	WO2004094468A2 Method for identifying an anti-streptococcal agent and its use for treating streptococcal infections
11/04/2004	WO2004094467A2 H. pylori antigens
11/04/2004	WO2004094465A2 Synthetic molecules that mimic chemokines
11/04/2004	WO2004094463A2 Peptide inhibitors of autophosphorylation protein kinases
11/04/2004	WO2004094462A2 Methods of peptide preparation
11/04/2004	WO2004094461A2 Human glucagon-like-peptide-1 mimics and their use in the treatment of diabetes and related conditions
11/04/2004	WO2004094457A2 Stable rgd peptidomimetic composition
11/04/2004	WO2004094455A2 Prophylactic and therapeutic benefits of new class of immune stimulating peptides
11/04/2004	WO2004094454A2 Hla-a2 tumor associated antigen peptides and compositions
11/04/2004	WO2004094452A2 Macrocyclic isoquinoline peptide inhibitors of hepatitis c virus
11/04/2004	WO2004093932A1 A seeded tear resistant scaffold
11/04/2004	WO2004093915A1 Pharmaceutical compositions for hepatitis c viral protease inhibitors
11/04/2004	WO2004093913A1 Treatment of hypertension
11/04/2004	WO2004093910A1 REMEDY FOR CEREBRAL NEURODEGENERATIVE DISEASES USING PPARδ AGONIST
11/04/2004	WO2004093903A2 Methods and compositions for immunomodulation using cd1 antigens
11/04/2004	WO2004093902A1 CONFORMATIONALLY CONSTRAINED PARATHYROID HORMONES WITH α-HELIX STABILIZERS
11/04/2004	WO2004093901A1 Compositions and methods for treating poxvirus infection
11/04/2004	WO2004093900A1 Apoptosis inducing agent and method of inducing apoptosis
11/04/2004	WO2004093899A1 Immunomodulatory product obtained from a bifidobacterium culture and compositions containing the same
11/04/2004	WO2004093898A2 Immunomodulatory product obtained from a bifidobacterium culture and compositions containing the same
11/04/2004	WO2004093897A1 Compositions for mucosal and oral administration comprising hcg fragments
11/04/2004	WO2004093895A1 Compositions of a cyclooxygenase-2 selective inhibitor and a potassium ion channel modulator for the treatment of pain, inflammation or inflammation mediated disorders
11/04/2004	WO2004093894A2 Use of b7-h3 as an immunoregulatory agent
11/04/2004	WO2004093893A2 Nogo-receptor antagonists for the treatment of conditions involving amyloid plaques
11/04/2004	WO2004093892A2 Stanniocalcin-1, variant or antagonists thereof for selective modulation of vascularization
11/04/2004	WO2004093854A2 Antineoplastic combinations
11/04/2004	WO2004093831A2 Cytokine-expressing cellular vaccine combinations
11/04/2004	WO2004093823A2 Polyethelene glycol link glp-1 compounds
11/04/2004	WO2004093807A2 Somatostatin vectors
11/04/2004	WO2004093797A2 Methods, devices, and compositions for lysis of occlusive blood clots while sparing wound sealing clots
11/04/2004	WO2004093787A2 Use of glycodendrimer reagents for inhibiting adhesion by microorganisms
11/04/2004	WO2004093783A2 Modulation of apolipoprotein c-iii expression
11/04/2004	WO2004093782A2 Tumor cytotoxicity induced by modulators of the cxcr4 receptor
11/04/2004	WO2004093662A2 Method for detecting prognosis of cancer
11/04/2004	WO2004093566A2 Functional animal muscle protein concentrate composition and process
11/04/2004	WO2004086039A8 A method for modulating nod1 activity, use of a mtp related molecule for modulating nod1 activity, and therapeutic applications thereof
11/04/2004	WO2004085471A3 Glp-2 derivatives
11/04/2004	WO2004083361A3 FVII OR FVIIa VARIANTS
11/04/2004	WO2004083245A3 Agent comprise an albumin-like first polypeptide bound to a second polypeptide
11/04/2004	WO2004083244A3 Specific inhibition of allograft rejection
11/04/2004	WO2004075912B1 Use of pgrp, lrrp and ctl proteins to trigger an anti-plasmodium immune response in anopheles species
11/04/2004	WO2004069194A3 Use of the oxidoreductase ncb50r for diagnosings and treating diabetes
11/04/2004	WO2004069192A3 Material and method for treating microbial mediated dermatological conditions
11/04/2004	WO2004067762A3 Crystallized structure of type iv collagen nc1 domain hexamer
11/04/2004	WO2004065572A3 Proteic binding partners of tctp and methods of modulating tumor reversion or cell apoptosis
11/04/2004	WO2004064786A3 Article for debridement and detoxification of wounds
11/04/2004	WO2004064780A3 Peptide-based angiogenesis inhibitors and methods of use thereof
11/04/2004	WO2004064713A3 The use of yop preoteins or rho gtpase inhibitors as caspase-1 inhibitors
11/04/2004	WO2004062585A3 Cytokine inhibition of eosinophils
11/04/2004	WO2004060319A3 Immunostimulatory combinations
11/04/2004	WO2004052177A3 Cell-based therapies for ischemia
11/04/2004	WO2004048421A3 Branched cationic copolymers and methods for antimicrobial use
11/04/2004	WO2004047747A3 Compositions and methods for cell dedifferentiation and tissue regeneration
11/04/2004	WO2004045592A3 Compounds and methods for increasing neurogenesis
11/04/2004	WO2004043356A3 Coated dibasic calcium phosphate
11/04/2004	WO2004043340A3 Alpha 5 beta 1 and its ability to regulate the cell survival pathway
11/04/2004	WO2004037167A3 Methods of treating dry eye disease with lantibiotics
11/04/2004	WO2004035798A3 Identification of e2f target genes and uses thereof
11/04/2004	WO2004035008A3 Treatment of infections and other disorders
11/04/2004	WO2004035007A3 Transmucosal administration of aggregated antigens
11/04/2004	WO2004030628A3 Adult bone marrow derived stem cells
11/04/2004	WO2004024173A3 A mechanism for hiv-1 entry into host cells and peptides inhibiting this mechanism
11/04/2004	WO2004022003A3 Materials and methods for treatment of allergic diseases
11/04/2004	WO2004020454A3 Modified transferrin fusion proteins comprising duplicate transferrin amino or carboxy terminal domains
11/04/2004	WO2004011484A3 Parathyroid hormone receptor activation and hematopoietic progenitor cell expansion
11/04/2004	WO2004005461A3 Antisense modulation of insulin-like growth factor 2 expression
11/04/2004	WO2004003000A3 1’-, 2'- and 3'- modified nucleoside derivatives for treating flaviviridae infections
11/04/2004	WO2004002417A3 Mammalian ch1 deleted mimetibodies, compositions, methods and uses
11/04/2004	WO2003104422A3 Mahoganoid polypeptides, and related compositions and methods
11/04/2004	WO2003103662A3 Inhibitors of glycoprotein vi
11/04/2004	WO2003102135A3 Control sequences of the human corin gene
11/04/2004	WO2003092612A3 VECTORS HAVING BOTH ISOFORMS OF β-HEXOSAMINIDASE
11/04/2004	WO2003091403A3 Genetic and epigenetic manipulation of abc transporters and ecto-phosphatases
11/04/2004	WO2003090512A3 Regeneration of endogenous myocardial tissue by induction of neovascularization
11/04/2004	WO2003089903A3 Compositions and methods relating to endothelial cell signaling using the protease activated receptor (par1)
11/04/2004	WO2003087115A3 Oligomeric compounds having modified phosphate groups
11/04/2004	WO2003082195A3 Protamine-adenoviral vector complexes and methods of use
11/04/2004	WO2003076593A3 Genomic screen for epigenetically silenced genes associated with cancer
11/04/2004	WO2003063799A3 Compositions and methods for systemic inhibition of cartilage degradation
11/04/2004	WO2003060091A3 Selective melanin-concentrating hormone type -1 receptor agonists
11/04/2004	WO2003055981A3 Methods of modulating heme oxygenase-1 expression and treating heme oxygenase-1 mediated conditions
11/04/2004	WO2003030828A3 Nociceptin-based analgesics
11/04/2004	WO2003029420A3 Apo-2 ligand variants and uses thereof
11/04/2004	WO2003015716A3 Immunoglobulin e vaccines and methods of use thereof
11/04/2004	WO2002092013A3 Methods for treating liver disease and liver damage with growth hormone and foxm1b
11/04/2004	WO2002081645A3 Cp27 peptides and their use in modulating cell growth and apoptosis
11/04/2004	WO2002072030A8 High affinity integrin polypeptides and uses thereof
11/04/2004	US20040220396 Polypeptide having an activity to support proliferation or survival of hematopoietic stem cell and hematopoietic progenitor cell, and dna coding for the same
11/04/2004	US20040220393 Modulation of HIF1alpha and HIF2alpha expression
11/04/2004	US20040220390 Composition useful for the treatment of tumors
11/04/2004	US20040220387 Allelic nucleotide sequences for diagnosis and prognosis of bipolar affective disorder; restriction fragment length polymorphisms and disease detection
11/04/2004	US20040220386 Light chain of botulinum toxin having structurally modified terminal ends which confers enhanced half-life and biological activity for use in prevention and treatment of neuromuscular and pain disorders; cosmetics
11/04/2004	US20040220383 Methods and materials relating to semaphorin-like polynucleotides
11/04/2004	US20040220274 Synergistic mixture of neurokinin receptor antagonist and phosphodiesterase inhibitor
11/04/2004	US20040220262 Transdermal and topical administration of drugs using basic permeation enhancers
11/04/2004	US20040220242 administering drug which suppress nitric oxide synthesis and antitrypsin drug
11/04/2004	US20040220239 Inhibitors of serine protease activity methods and compositions for treatment of nitric oxide-induced clinical conditions

1 ... 1539 1540 1541 1542 1543 1544 1545 1546 1547 1548 1549 1550 1551 1552 1553 1554 1555 1556 1557 1558 1559 ... 3163